PMID- 24446485
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20181202
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 170
IP  - 4
DP  - 2014 Apr
TI  - MicroRNA expression patterns associated with hyperfunctioning and 
      non-hyperfunctioning phenotypes in adrenocortical adenomas.
PG  - 583-91
LID - 10.1530/EJE-13-0817 [doi]
AB  - BACKGROUND: The adrenocortical adenoma (ACA) entity includes 
      aldosterone-producing adenoma (APA), cortisol-producing adenoma (CPA), and 
      non-hyperfunctioning adenoma (NHFA) phenotypes. While gene mutations and mRNA 
      expression profiles have been partly characterized, less is known about the 
      alterations involving microRNA (miRNA) expression. AIM: To characterize miRNA 
      expression profile in relation to the subtypes of ACAs. SUBJECTS AND METHODS: 
      miRNA expression profiles were determined in 26 ACAs (nine APAs, ten CPAs, and 
      seven NHFAs) and four adrenal references using microarray-based screening. 
      Significance analysis of microarrays (SAM) was carried out to identify 
      differentially expressed miRNAs between ACA and adrenal cortices or between tumor 
      subtypes. Selected differentially expressed miRNAs were validated in an extended 
      series of 43 ACAs and ten adrenal references by quantitative RT-PCR. RESULTS: An 
      hierarchical clustering revealed separate clusters for APAs and CPAs, while the 
      NHFAs were found spread out within the APA/CPA clusters. When NHFA was excluded, 
      the clustering analysis showed a better separation between APA and CPA. SAM 
      analysis identified 40 over-expressed and three under-expressed miRNAs in the 
      adenomas as compared with adrenal references. Fourteen miRNAs were common among 
      the three ACA subtypes. Furthermore, we found specific miRNAs associated with 
      different tumor phenotypes. CONCLUSION: The results suggest that miRNA expression 
      profiles can distinguish different subtypes of ACA, which may contribute to a 
      deeper understanding of ACA development and potential therapeutics.
FAU - Velazquez-Fernandez, David
AU  - Velazquez-Fernandez D
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Caramuta, Stefano
AU  - Caramuta S
FAU - Ozata, Deniz M
AU  - Ozata DM
FAU - Lu, Ming
AU  - Lu M
FAU - Hoog, Anders
AU  - Hoog A
FAU - Backdahl, Martin
AU  - Backdahl M
FAU - Larsson, Catharina
AU  - Larsson C
FAU - Lui, Weng-Onn
AU  - Lui WO
FAU - Zedenius, Jan
AU  - Zedenius J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140308
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (MicroRNAs)
RN  - 4964P6T9RB (Aldosterone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex/*metabolism
MH  - Adrenal Cortex Neoplasms/*genetics/metabolism
MH  - Adrenocortical Adenoma/*genetics/metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aldosterone/metabolism
MH  - Cohort Studies
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Hydrocortisone/metabolism
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Oligonucleotide Array Sequence Analysis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Young Adult
EDAT- 2014/01/22 06:00
MHDA- 2014/05/03 06:00
CRDT- 2014/01/22 06:00
PHST- 2014/01/22 06:00 [entrez]
PHST- 2014/01/22 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - EJE-13-0817 [pii]
AID - 10.1530/EJE-13-0817 [doi]
PST - epublish
SO  - Eur J Endocrinol. 2014 Mar 8;170(4):583-91. doi: 10.1530/EJE-13-0817. Print 2014 
      Apr.